TrovaGene, Inc. - Unit
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TROVU and buy or sell other stocks, ETFs, and their options commission-free!About TROVU
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
CEOMark Erlander, PhD
CEOMark Erlander, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1999
Founded1999
Employees—
Employees—
TROVU Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume825.89
Average volume825.89
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$17.69
52 Week high$17.69
52 Week low$1.50
52 Week low$1.50
Stock Snapshot
The current TrovaGene, Inc. - Unit(TROVU) stock price is $1.68.
On 2025-12-05, TrovaGene, Inc. - Unit(TROVU) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for TrovaGene, Inc. - Unit(TROVU) stock has reached 0, versus its average volume of 825.89.
The stock's 52-week range extends from a low of $1.50 to a high of $17.69.
The stock's 52-week range extends from a low of $1.50 to a high of $17.69.